title: Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
abstract: OBJECTIVE
  Clinical studies show that Asians (ASN) are more susceptible to toxicities associated with platinum-containing regimens. We hypothesized that studying ASN as an 'enriched phenotype' population could enable the discovery of novel genetic determinants of platinum susceptibility.
  
  
  METHODS
  Using well-genotyped lymphoblastoid cell lines from the HapMap, we determined cisplatin and carboplatin cytotoxicity phenotypes (IC50s) for ASN, Caucasians (CEU), and Africans (YRI). IC50s were used in genome-wide association studies.
  
  
  RESULTS
  ASN were most sensitive to platinums, corroborating clinical findings. ASN genome-wide association studies produced 479 single-nucleotide polymorphisms (SNPs) associating with cisplatin susceptibility and 199 with carboplatin susceptibility (P<10). Considering only the most significant variants (P<9.99x10), backwards elimination was then used to identify reduced-model SNPs, which robustly described the drug phenotypes within ASN. These SNPs comprised highly descriptive genetic signatures of susceptibility, with 12 SNPs explaining more than 95% of the susceptibility phenotype variation for cisplatin, and eight SNPs approximately 75% for carboplatin. To determine the possible function of these variants in ASN, the SNPs were tested for association with differential expression of target genes. SNPs were highly associated with the expression of multiple target genes, and notably, the histone H3 family was implicated for both drugs, suggesting a platinum-class mechanism. Histone H3 has repeatedly been described as regulating the formation of platinum-DNA adducts, but this is the first evidence that specific genetic variants might mediate these interactions in a pharmacogenetic manner. Finally, to determine whether any ASN-identified SNPs might also be important in other human populations, we interrogated all 479/199 SNPs for association with platinum susceptibility in an independent combined CEU/YRI population. Three unique SNPs for cisplatin and 10 for carboplatin replicated in CEU/YRI.
  
  
  CONCLUSIONS
  Enriched 'platinum susceptible' populations can be used to discover novel genetic determinants governing interindividual platinum chemotherapy susceptibility.
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA.
authors.forename: Peter H
authors.initials: PH
authors.lastname: O'Donnell
authors.forename: Eric
authors.initials: E
authors.lastname: Gamazon
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Amy L
authors.initials: AL
authors.lastname: Stark
authors.forename: Emily O
authors.initials: EO
authors.lastname: Kistner-Griffin
authors.forename: R
authors.initials: R
authors.lastname: Stephanie Huang
authors.forename: M
authors.initials: M
authors.lastname: Eileen Dolan
mesh_terms: D044466:Asian People; D044383:Black People; D016190:Carboplatin / Q000494:pharmacology; D002461:Cell Line, Transformed; D002945:Cisplatin / Q000494:pharmacology; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005828:Genetics, Population; D055106:Genome-Wide Association Study; D006801:Humans; D020128:Inhibitory Concentration 50; D008214:Lymphocytes / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype; D010984:Platinum / Q000494:pharmacology*; D044465:White People
chemical_list: D010984:Platinum; D016190:Carboplatin; D002945:Cisplatin
references.citation: Clin Cancer Res. 2005 Feb 15;11(4):1534-8
references.pmid: 15746057
references.citation: Biochim Biophys Acta. 2002 Dec 12;1579(2-3):142-52
references.pmid: 12427549
references.citation: J Biol Chem. 2004 May 14;279(20):20622-5
references.pmid: 15010460
references.citation: Eur J Cancer Clin Oncol. 1988 Feb;24(2):255-62
references.pmid: 3281842
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):287-94
references.pmid: 18714314
references.citation: Nat Chem Biol. 2008 Feb;4(2):110-2
references.pmid: 18157123
references.citation: Cancer Res. 2004 Jun 15;64(12):4353-6
references.pmid: 15205351
references.citation: Lung Cancer. 2007 Aug;57(2):143-51
references.pmid: 17420066
references.citation: Nat Genet. 2007 Oct;39(10):1217-24
references.pmid: 17873874
references.citation: Am J Hum Genet. 2007 Sep;81(3):559-75
references.pmid: 17701901
references.citation: Cell. 2010 Jan 22;140(2):183-95
references.pmid: 20141833
references.citation: Jpn J Clin Oncol. 2002 Feb;32(2):48-53
references.pmid: 11948228
references.citation: PLoS Genet. 2010 Apr 01;6(4):e1000888
references.pmid: 20369019
references.citation: Am J Hum Genet. 1999 Dec;65(6):1718-24
references.pmid: 10577926
references.citation: J Clin Oncol. 1996 Mar;14(3):1043-4
references.pmid: 8622011
references.citation: Oncol Rep. 2003 Jul-Aug;10(4):951-5
references.pmid: 12792751
references.citation: PLoS Genet. 2009 Aug;5(8):e1000592
references.pmid: 19662163
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):417-23
references.pmid: 18615002
references.citation: Immunobiology. 2003;207(5):351-9
references.pmid: 14575150
references.citation: Hum Hered. 2007;63(2):85-92
references.pmid: 17283437
references.citation: Cancer Res. 2007 Jun 1;67(11):5425-33
references.pmid: 17545624
references.citation: Nat Genet. 2007 Feb;39(2):226-31
references.pmid: 17206142
references.citation: Clin Cancer Res. 2006 Jan 1;12(1):131-8
references.pmid: 16397034
references.citation: Pharmacogenomics. 2005 Apr;6(3):303-10
references.pmid: 16013961
references.citation: Cancer Treat Rev. 2007 Oct;33(6):565-77
references.pmid: 17707593
references.citation: Nature. 2005 Oct 27;437(7063):1299-320
references.pmid: 16255080
references.citation: Ann Oncol. 2003 Mar;14(3):449-54
references.pmid: 12598352
references.citation: Anticancer Drugs. 2003 Nov;14(10):801-7
references.pmid: 14597874
references.citation: Hum Genomics. 2009 Jan;3(2):128-42
references.pmid: 19164090
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4513-5
references.pmid: 17925544
references.citation: Nat Rev Genet. 2005 Feb;6(2):95-108
references.pmid: 15716906
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63
references.pmid: 17537913
references.citation: Nat Genet. 2007 Oct;39(10):1202-7
references.pmid: 17873877
references.citation: Pharmacogenet Genomics. 2008 Mar;18(3):253-62
references.pmid: 18300947
references.citation: PLoS One. 2009;4(3):e4684
references.pmid: 19259268
references.citation: Int J Oncol. 2004 Jun;24(6):1407-12
references.pmid: 15138581
references.citation: Mol Cancer Ther. 2007 Jan;6(1):31-6
references.pmid: 17237264
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
references.pmid: 12883005
references.citation: Am J Hum Genet. 2007 Sep;81(3):427-37
references.pmid: 17701890
references.citation: Cancer Treat Rev. 2007 Feb;33(1):9-23
references.pmid: 17084534